血磷在脓毒症中临床意义的研究进展

doi:10.3969/j.issn.1674-490X.2023.02.005

摘要/Abstract

摘要： 脓毒症是感染所致的危及生命的急危重症,血磷在脓毒症的发生发展中扮演着重要的角色。血磷是机体的重要组成成分,具有许多生物活性,参与细胞膜磷脂双分子层的组成,维持细胞膜结构完整和功能正常。此外血磷作为三磷酸腺苷酶的组成成分,参与能量代谢。在氧的运输、调节酶促反应以及维持酸碱平衡方面也发挥重要作用。脓毒症患者常常出现低磷血症,并与多脏器功能障碍有关。现总结脓毒症中血磷的变化,为脓毒症的进一步研究和治疗提供新思路。

关键词: 脓毒症, 血磷, 多脏器功能障碍, 危重症, 预后

Abstract: Sepsis is a life-threatening critical illness caused by infection. Serum phosphorus plays an important role in the process of sepsis. Phosphorus is an element component of the body with many biological activities. It participates in the composition of the cell membrane phospholipid bilayer and maintains the normal structure and function of cell membrane. In addition, phosphorus as a component of ATP enzyme is involved in energy storage and transport. It also plays an important role in oxygen delivery, regulation of enzyme activity, and maintenance of acid-base balance in the body. Patients with sepsis often have hypophosphatemia, which is related to multiple organ dysfunction. This paper summarizes the changes of serum phosphorus in sepsis, and provides a new idea for further research and treatment of sepsis.

Key words: sepsis, serum phosphorus, multiple organ dysfunction, critical illness, prognosis

中图分类号:

路潇,梁璐. 血磷在脓毒症中临床意义的研究进展[J]. 医学研究与教育, 2023, 40(2): 33-38.

参考文献

[1] NAPOLITANO L M. Sepsis 2018: definitions and guideline changes[J]. Surg Infect(Larchmt), 2018, 19(2): 117-125. DOI: 10.1089/sur.2017.278.
[2] ARINA P, SINGER M. Pathophysiology of sepsis[J]. Curr Opin Anaesthesiol, 2021, 34(2): 77-84. DOI: 10.1097/aco.0000000000000963.
[3] 张笑婷,纪文焘,薄禄龙,等.脓毒症基础研究的进展及未来方向[J].中华危重病急救医学, 2021, 33(8): 919-921. DOI: 10.3760/cma.j.cn121430-20210126-00132.
[4] 何雪梅,薄禄龙,姜春玲.脓毒症免疫抑制与免疫刺激治疗的研究进展[J].中华危重病急救医学, 2018, 30(12): 1202-1205. DOI: 10.3760/cma.j.issn.2095-4352.2018.12.020.
[5] 梁娜,祝益民.脓毒症高代谢的研究进展[J].中国小儿急救医学, 2014, 21(12): 807-809. DOI: 10.3760/cma.j.issn.1673-4912.2014.12.018.
[6] 付阳,陈捷,蔡蓓,等.血清降钙素原和免疫炎性因子C反应蛋白、白介素-6、血清淀粉样蛋白A在脓毒血症中的诊断价值[J].四川大学学报(医学版), 2012, 43(5): 702-705. DOI: 10.13464/j.scuxbyxb.2012.05.036.
[7] FAIX J D. Biomarkers of sepsis[J]. Crit Rev Clin Lab Sci, 2013, 50(1): 23-36. DOI: 10.3109/10408363.2013.764490.
[8] 张建群.低磷血症在危重症患者中的临床意义及研究进展[J].中国现代药物应用, 2014, 8(12): 240-242. DOI: 10.14164/j.cnki.cn11-5581/r.2014.12.108.
[9] ZAVATTA G, ALTIERI P, VANDI G, et al. Phosphate metabolism and pathophysiology in parathyroid disorders and endocrine tumors[J]. Int J Mol Sci, 2021, 22(23): 12975. DOI: 10.3390/ijms222312975.
[10] MANGHAT P, SODI R, SWAMINATHAN R. Phosphate homeostasis and disorders[J]. Ann Clin Biochem, 2014, 51(pt 6): 631-656. DOI: 10.1177/0004563214521399.
[11] LEUNG J, CROOK M. Disorders of phosphate metabolism[J]. J Clin Pathol, 2019, 72(11): 741-747. DOI: 10.1136/jclinpath-2018-205130.
[12] PENIDO M G M G, ALON U S. Phosphate homeostasis and its role in bone health[J]. Pediatr Nephrol, 2012, 27(11): 2039-2048. DOI: 10.1007/s00467-012-2175-z.
[13] BHADADA S K, RAO S D. Role of phosphate in biomineralization[J]. Calcif Tissue Int, 2021, 108(1): 32-40. DOI: 10.1007/s00223-020-00729-9.
[14] BLAINE J, CHONCHOL M, LEVI M. Renal control of calcium, phosphate, and magnesium homeostasis[J]. Clin J Am Soc Nephrol, 2015, 10(7): 1257-1272. DOI: 10.2215/cjn.09750913.
[15] URSEM S R, VERVLOET M G, DE JONGH R T, et al. Oxidation of parathyroid hormone[J]. Clin Chim Acta, 2020, 506: 84-91. DOI: 10.1016/j.cca.2020.03.020.
[16] LOMBARDI G, ZIEMANN E, BANFI G, et al. Physical activity-dependent regulation of parathyroid hormone and calcium-phosphorous metabolism[J]. Int J Mol Sci, 2020, 21(15): 5388. DOI: 10.3390/ijms21155388.
[17] TINAWI M. Disorders of calcium metabolism: hypocalcemia and hypercalcemia[J]. Cureus, 2021, 13(1): e12420. DOI: 10.7759/cureus.12420.
[18] DEBOWSKA M, DAI L, WOJCIK-ZALUSKA A, et al. Association between biomarkers of mineral and bone metabolism and removal of calcium and phosphate in hemodialysis[J]. Blood Purif, 2020, 49(1/2): 71-78. DOI: 10.1159/000503623.
[19] MANTOVANI G, ELLI F M. PTH resistance[J]. Mol Cell Endocrinol, 2021, 531: 111311. DOI: 10.1016/j.mce.2021.111311.
[20] KHUNDMIRI S J, MURRAY R D, LEDERER E. PTH and vitamin D[J]. Compr Physiol, 2016, 6(2): 561-601. DOI: 10.1002/cphy.c140071.
[21] SONG L. Calcium and bone metabolism indices[J]. Adv Clin Chem, 2017, 82: 1-46. DOI: 10.1016/bs.acc.2017.06.005.
[22] BIENAIMÉ F, PRIÉ D, FRIEDLANDER G, et al. Vitamin D metabolism and activity in the parathyroid gland[J]. Mol Cell Endocrinol, 2011, 347(1/2): 30-41. DOI: 10.1016/j.mce.2011.05.031.
[23] NIEDZIELA N, PIERZCHAŁA K, ZALEJSKA-FIOLKA J, et al. Assessment of biochemical and densitometric markers of calcium-phosphate metabolism in the groups of patients with multiple sclerosis selected due to the serum level of vitamin D3[J]. Biomed Res Int, 2018, 2018: 9329123. DOI: 10.1155/2018/9329123.
[24] 杨凡.维生素D: 综述和指南解读[J].中华妇幼临床医学杂志(电子版), 2010, 6(4): 229-230. DOI: 10.3969/cma.j.issn.1673-5250.2010.04.001.
[25] MATTHIAS J, CUI Q X, SHUMATE L T, et al. Extra-large Gα protein(XLαs)deficiency causes severe adenine-induced renal injury with massive FGF23 elevation[J]. Endocrinology, 2020, 161(1): bqz025. DOI: 10.1210/endocr/bqz025.
[26] RODRÍGUEZ M. FGF23: is it another biomarker for phosphate-calcium metabolism?[J]. Adv Ther, 2020, 37(2): 73-79. DOI: 10.1007/s12325-019-01181-4.
[27] IMEL E A, BIGGIN A, SCHINDELER A, et al. FGF23, hypophosphatemia, and emerging treatments[J]. JBMR Plus, 2019, 3(8): e10190. DOI: 10.1002/jbm4.10190.
[28] AL HARBI S A, AL-DORZI H M, AL MESHARI A M, et al. Association between phosphate disturbances and mortality among critically ill patients with sepsis or septic shock[J]. BMC Pharmacol Toxicol, 2021, 22(1): 30. DOI: 10.1186/s40360-021-00487-w.
[29] ARIYOSHI N, NOGI M, ANDO A, et al. Hypophosphatemia-induced cardiomyopathy[J]. Am J Med Sci, 2016, 352(3): 317-323. DOI: 10.1016/j.amjms.2016.04.013.
[30] GEERSE D A, BINDELS A J, KUIPER M A, et al. Treatment of hypophosphatemia in the intensive care unit: a review[J]. Crit Care, 2010, 14(4): R147. DOI: 10.1186/cc9215.
[31] BARAK V, SCHWARTZ A, KALICKMAN I, et al. Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines[J]. Am J Med, 1998, 104(1): 40-47. DOI: 10.1016/s0002-9343(97)00275-1.
[32] ZHAO J N, TAN Y, WANG L, et al. Serum sphingosine-1-phosphate levels and Sphingosine-1-Phosphate gene polymorphisms in acute respiratory distress syndrome: a multicenter prospective study[J]. J Transl Med, 2020, 18(1): 156. DOI: 10.1186/s12967-020-02322-y.
[33] 王颖勤,钟鸣,诸杜明.鞘氨醇-1-磷酸在脓毒症中调节作用的研究进展[J].中国临床医学, 2018, 25(6): 977-982. DOI: 10.12025/j.issn.1008-6358.2018.20180150.
[34] SHEU C C, GONG M N, ZHAI R, et al. Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS[J]. Chest, 2010, 138(3): 559-67. DOI: 10.1378/chest.09-2933.
[35] LIU Y C, YU M M, SHOU S T, et al. Sepsis-induced cardiomyopathy: mechanisms and treatments[J]. Front Immunol, 2017, 8: 1021. DOI: 10.3389/fimmu.2017.01021.
[36] O'CONNOR L R, WHEELER W S, BETHUNE J E. Effect of hypophosphatemia on myocardial performance in man[J]. N Engl J Med, 1977, 297(17): 901-903. DOI: 10.1056/NEJM197710272971702.
[37] CLAUDIUS I, SACHS C, SHAMJI T. Hypophosphatemia-induced heart failure[J]. Am J Emerg Med, 2002, 20(4): 369-370. DOI: 10.1053/ajem.2002.33950.
[38] 肖瑶.低磷血症的发生及其对机体的影响[J].临床和实验医学杂志, 2007, 6(4): 161-163. DOI: 10.3969/j.issn.1671-4695.2007.04.119.
[39] 李婉丽,李建国.脓毒症相关性血小板减少症的研究及治疗进展[J].大连医科大学学报, 2018, 40(6): 549-552. DOI: 10.11724/jdmu.2018.06.16.